Remedy Plan Therapeutics
- Biotech or pharma, therapeutic R&D
Remedy Plan Therapeutics is a privately held, clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, with a pipeline of novel, hyperbolic NAMPT inhibitors. Remedy Plan's novel NAMPT inhibitors have broad therapeutic applications in cancer, autoimmune, and metabolic diseases. Our lead asset RPT1G is currently in a Phase 1 trial in healthy volunteers and will be advancing into oncology later this year. We are exploring future lead investors and strategic partners. We will be presenting at BIO on Monday, June 16 at 2:30 PM in Room 154.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}